Cytokinetics, Incorporated
CYTK
$39.48
$0.330.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -150.02M | -160.55M | -143.32M | -135.64M | -136.90M |
| Total Depreciation and Amortization | 2.38M | 2.41M | 2.41M | 2.33M | 6.34M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.35M | 46.75M | 31.83M | 29.51M | 11.65M |
| Change in Net Operating Assets | 41.71M | 9.88M | 9.77M | -25.70M | 44.88M |
| Cash from Operations | -65.57M | -101.50M | -99.31M | -129.51M | -74.04M |
| Capital Expenditure | -1.29M | -701.00K | -1.92M | -- | -77.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 112.15M | -44.35M | -649.63M | 32.64M | -81.33M |
| Cash from Investing | 110.86M | -45.05M | -651.55M | 32.64M | -81.41M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.91M | -2.89M | -2.88M | -932.00K | -222.00K |
| Issuance of Common Stock | 6.48M | 6.32M | 623.89M | 123.17M | 169.02M |
| Repurchase of Common Stock | -1.18M | 0.00 | 0.00 | -18.45M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 200.00M | -- | 0.00 |
| Cash from Financing | 2.38M | 3.43M | 821.01M | 103.79M | 168.80M |
| Foreign Exchange rate Adjustments | 292.00K | -126.00K | 16.00K | 27.00K | -20.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.97M | -143.25M | 70.17M | 6.95M | 13.33M |